New chemo combo could improve outcomes for stomach cancer patients
NCT ID NCT07366528
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether a chemotherapy combination of oxaliplatin plus S-1 works as well as or better than docetaxel plus S-1 for stage III gastric cancer patients who have had surgery. About 387 adults aged 18 to 80 will be randomly assigned to one of the two treatments. The main goal is to see how many patients remain cancer-free after three years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oxaliplatin plus S-1 or docetaxel plus S-1
What this could lead to
If successful, this could identify a more effective or less toxic chemotherapy option for stage III gastric cancer patients after surgery.
What could go wrong
This is a non-inferiority trial, so the new combo may not be better than the standard. Side effects from chemotherapy are expected and can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER (GC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
NOT_YET_RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Renji Hospital
NOT_YET_RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ruijin Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Tenth People's Hospital
NOT_YET_RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yuebei People's Hospital
NOT_YET_RECRUITINGShaoguan, Guandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••